{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:21:59Z","timestamp":1789543319685,"version":"build-2803163510"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III-Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["FIS PI12\/02267"],"award-info":[{"award-number":["FIS PI12\/02267"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III-Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["FIS PI13\/01768"],"award-info":[{"award-number":["FIS PI13\/01768"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Vemurafenib is a newly licensed target-directed medication. It has been proven to improve the survival of patients with metastatic melanoma and the BRAFV600E mutation; however, adverse cutaneous reactions are frequent. Few cases of life-threatening severe cutaneous adverse reactions (SCARs) induced by vemurafenib have been reported. Dabrafenib, another selective BRAF inhibitor, has been licensed recently as an alternative drug with the same indications. From a molecular point of view, both vemurafenib and dabrafenib contain a sulfonamide group; cross-reactivity to sulfonamide compounds has been reported in allergic patients. We report on a patient with vemurafenib-induced toxic epidermal necrolysis (TEN). In vitro analysis of lymphocyte reactivity to vemurafenib showed positive results, confirming drug causality. In addition, lymphocytes from the patient reacted to dabrafenib and to the antibiotic sulfonamide drug sulfamethoxazole. Moreover, lymphocytes from two patients with cutaneous adverse reactions to sulfamethoxazole also reacted to vemurafenib and dabrafenib in vitro. These data strongly suggest that there might be clinical cross-reactivity between BRAF inhibitors and sulfonamides in some patients. Thus, precautions should be taken to avoid sulfonamide drugs as much as possible in patients showing serious hypersensitivity reactions to vemurafenib and vice versa.<\/jats:p>","DOI":"10.1111\/bjd.14201","type":"journal-article","created":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T05:58:46Z","timestamp":1443419926000},"page":"621-624","source":"Crossref","is-referenced-by-count":30,"title":["Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds"],"prefix":"10.1093","volume":"174","author":[{"given":"T.","family":"Bell\u00f3n","sequence":"first","affiliation":[{"name":"Institute for Health Research University Hospital La Paz\u2013IdiPAZ P\u00b0 Castellana 261 28046 Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Lerma","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit Principe de Asturias University Hospital Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Gonz\u00e1lez-Valle","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital of Getafe Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gonz\u00e1lez Herrada","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital of Getafe Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.J.","family":"de Abajo","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit Principe de Asturias University Hospital Madrid Spain"},{"name":"Department of Biomedical Sciences (Pharmacology) University of Alcal\u00e1 Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,3,1]]},"reference":[{"key":"2023033115535284900_","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"2023033115535284900_","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl JMed"},{"key":"2023033115535284900_","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12010","article-title":"Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities","volume":"167","author":"Sinha","year":"2012","journal-title":"Br J Dermatol"},{"key":"2023033115535284900_","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/CMR.0b013e3283573437","article-title":"Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib","volume":"22","author":"Minor","year":"2012","journal-title":"Melanoma Res"},{"key":"2023033115535284900_","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.annder.2013.10.054","article-title":"Vemurafenib-induced toxic epidermal necrolysis","volume":"141","author":"Wantz","year":"2014","journal-title":"Ann Dermatol Venereol"},{"key":"2023033115535284900_","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/bjd.12796","article-title":"Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma","volume":"170","author":"Sinha","year":"2014","journal-title":"Br J Dermatol"},{"key":"2023033115535284900_","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/bjd.13522","article-title":"Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis","volume":"172","author":"Jeudy","year":"2015","journal-title":"Br J Dermatol"},{"key":"2023033115535284900_","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ad.2015.03.008","article-title":"Toxic epidermal necrolysis induced by vemurafenib","volume":"106","author":"Lapresta","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"2023033115535284900_","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1398-9995.2004.00547.x","article-title":"The lymphocyte transformation tests in the diagnosis of drug hypersensitivity","volume":"59","author":"Pichler","year":"2004","journal-title":"Allergy"},{"key":"2023033115535284900_","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"2023033115535284900_","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000312632","article-title":"Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole","volume":"153","author":"Zawodniak","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"key":"2023033115535284900_","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jaci.2007.02.007","article-title":"Cross-reactivity patterns of T cells specific for iodinated contrast media","volume":"119","author":"Lerch","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"2023033115535284900_","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2133.2008.08875.x","article-title":"Lymphocyte proliferation response in patients with delayed hypersensitivity reactions to heparins","volume":"160","author":"L\u00f3pez","year":"2009","journal-title":"Br J Dermatol"},{"key":"2023033115535284900_","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1398-9995.2008.01924.x","article-title":"Update on the evaluation of hypersensitivity reactions to betalactams","volume":"64","author":"Blanca","year":"2009","journal-title":"Allergy"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.14201","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/174\/3\/621\/49716447\/bjd0621.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/174\/3\/621\/49716447\/bjd0621.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T17:05:45Z","timestamp":1692032745000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/174\/3\/621\/6617124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,1]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,1]]},"published-print":{"date-parts":[[2016,3,1]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.14201","relation":{},"ISSN":["1365-2133","0007-0963"],"issn-type":[{"value":"1365-2133","type":"electronic"},{"value":"0007-0963","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,3,1]]},"published":{"date-parts":[[2016,3,1]]}}}